Other reasons that can increase your risk of tendon problems can include:Stop taking Ofloxacin immediately and get medical help right away at the first sign of tendon pain, swelling or inflammation.Talk to your healthcare provider about the risk of tendon rupture with continued use of Ofloxacin tablets.Tendon rupture can happen while you are taking or after you have finished taking Ofloxacin tablets.Get medical help right away if you get any of the following signs or symptoms of a tendon rupture:2. Confirmation of positive opiate screens by more specific methods may be necessary.Long-term studies to determine the carcinogenic potential of Ofloxacin have not been conducted.Ofloxacin was not mutagenic in the Ames bacterial test, Ofloxacin has not been shown to have any teratogenic effects at oral doses as high as 810 mg/kg/day (11 times the recommended maximum human dose based on mg/mThere are, however, no adequate and well-controlled studies in pregnant women. In addition, avoid the use of fluoroquinolones, including Ofloxacin, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones.Fluoroquinolones, including Ofloxacin, have been associated with an increased risk of tendinitis and tendon rupture in all ages. Clinical manifestations may include one or more of the following:The drug should be discontinued immediately at the first appearance of skin rash, jaundice, or any other sign of hypersensitivity and supportive measures instituted (see If CDAD is suspected or confirmed, ongoing antibiotic use not directed against Fluoroquinolones, including Ofloxacin, have been associated with aortic aneurysm and dissection. Because Ofloxacin is known to be substantially excreted by the kidney, and elderly patients are more likely to have decreased renal function, dosage adjustment is necessary for elderly patients with impaired renal function as recommended for all patients. 361.4Ofloxacin, USP is an off-white to pale yellow crystalline p… Chemically, Ofloxacin, USP, a fluorinated carboxyquinolone, is the racemate, (±)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid. The relative solubility characteristics of Ofloxacin, USP at room temperature, as defined by USP nomenclature, indicate that Ofloxacin, USP is considered to be Ofloxacin Tablets, USP contain the following inactive ingredients: lactose monohydrate, pregelatinized maize starch, hydroxy propyl methyl cellulose, talc, magnesium stearate, polyethylene glycol, sodium starch glycolate, and titanium dioxide.
Guelpa-Lauras CC, Perani EG, Giroir AM, Grosset JH.Int J Lepr Other Mycobact Dis.
A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable; other therapy should be selected.Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. (see Some quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion). Therefore, if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives, the prothrombin time or other suitable coagulation test should be closely monitored.Since disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concurrently with quinolones and an antidiabetic agent, careful monitoring of blood glucose is recommended when these agents are used concomitantly (see Some quinolones, including Ofloxacin, may produce false-positive urine screening results for opiates using commercially available immunoassay kits. The pharmacokinetic properties of Ofloxacin in elderly subjects are similar to those in younger subjects. Peak plasma concentrations were 114% and 54% higher in elderly females compared to elderly males following single and multiple twice-daily doses. This drug should be discontinued immediately at the first appearance of a skin rash or any other sign of hypersensitivity. Dosage adjustment is necessary for elderly patients with impaired renal function (creatinine clearance rate ≤ 50 mL/min) due to reduced clearance of Ofloxacin. Patients should be informed of this potential side effect and advised to discontinue Ofloxacin and contact their healthcare provider if any symptoms of tendinitis or tendon rupture occur (See In phase 2/3 clinical trials with Ofloxacin, 688 patients (14.2%) were ≥ 65 years of age.